COVID-19 clinical outcomes in patients with and without ongoing therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

Background: The are conflicting reports on the effects of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) continued treatment clinical outcomes in COVID-19 patients. Material and methods: Patients presented with symptoms suggestive infection were enrolled between 5 April 2021,and June 2021. who survived acute stage disease asked to attend out-patient clinic after six months following diagnosis. Results : A total 162 patients this study. ARB users showed significant independent association lower fatality rate as compared ACEI/ARB-naïve [OR (CI) = 0.1(0.0–0.5), p 0.01]. prevalence respiratory support use intensive care unit (ICU) admission was numerically, but not statically significant, among than non-ARB users. distribution in-hospital adverse outcome numerically ACEI non users, though did reach statistical significance. persistent cough 2 (1.1–10), 0.02]. No differences other long term found nonusers. On hand, chest pain higher non-ACEI After adjusting for baseline comorbidities, user persisted. Conclusion: low ARB/ACEI cough.